Veliparib hydrochloride hmoov, tseem hu ua ABT888 hmoov, yog ib yam tshuaj uas yog nyob rau hauv cov chav kawm ntawm cov tshuaj hu ua PARP inhibitors (poly (ADP-ribose) polymerase inhibitors). Ib qho enzyme hu ua PARP pab kho DNA puas hauv hlwb. Los ntawm inhibiting PARP, veliparib cuam tshuam nrog kev kho DNA puas hauv cov kab mob, uas tuaj yeem ua rau cov cell tuag, tshwj xeeb tshaj yog cov uas twb puas lawm los ntawm kev hloov caj ces lossis lwm yam. Kev kho mob qog noj ntshav ntawm zes qe menyuam, mob qog noj ntshav mis, mob qog noj ntshav prostate, thiab cov qog nqaij hlav tsis me me (NSCLC) raug tshawb xyuas, suav nrog veliparib HCl. Txhawm rau ua kom muaj txiaj ntsig ntawm lwm cov kev kho mob, xws li kev kho hluav taws xob lossis tshuaj khomob, nws nquag ua ke nrog lawv. Los ntawm kev tiv thaiv kev kho DNA kev puas tsuaj los ntawm cov kev kho mob no, veliparib tuaj yeem txhim kho tag nrho cov txiaj ntsig ntawm kev kho rau cov kab mob. Raws li kev tshawb nrhiav tshuaj, nws txoj kev siv thiab kev ua tau zoo tseem tab tom kawm hauv kev sim tshuaj ntsuam xyuas los txiav txim siab txoj hauv kev zoo tshaj plaws los muab nws tso rau hauv kev kho kab mob.
Veliparib Mechanism Ntawm Kev Ua
Veliparib (ABT-888) ua haujlwm feem ntau los ntawm inhibiting cov haujlwm ntawm enzyme poly (ADP-ribose) polymerase (PARP). PARP enzymes yog qhov tseem ceeb hauv kev kho ib leeg-strand so (SSBs) hauv DNA ntawm lub hauv paus kev kho kom zoo. Hauv qab no yog cov lus piav qhia ntxaws txog nws cov txheej txheem ntawm kev txiav txim:
1. PARP inhibition: Veliparib khi rau PARP enzymes, tshwj xeeb PARP-1 thiab PARP-2, inhibiting lawv cov haujlwm. Qhov no tiv thaiv PARP los ntawm kev ua kom cov kev kho ntawm ib leeg-strand DNA so.
2. DNA puas tsub zuj zuj: Thaum PARP yog inhibited, ib leeg-strand so accumulates. Thaum lub sijhawm DNA rov ua dua, cov kev so no tuaj yeem ua rau muaj kev sib cais ntawm ob-strand so (DSBs) yog tias tsis kho raws sijhawm.
3. Synthetic lethality: Veliparib exploits lub tswvyim ntawm synthetic lethality, uas yog tshwj xeeb tshaj yog zoo nyob rau hauv cov kab mob ntawm cov kab mob uas tsis xws luag nyob rau hauv lwm yam DNA kho txoj kev, xws li cov uas muaj BRCA1 los yog BRCA2 kev hloov. Hauv cov hlwb nrog cov kev hloov pauv no, homologous recombination kho (HRR) txoj hauv kev rau DSBs twb puas lawm. Ntxiv inhibition ntawm PARP thaiv kev kho ntawm SSBs thiab ua rau tsub zuj zuj ntawm DSBs, uas lub cell tsis tuaj yeem kho tau zoo, ua rau kev tuag ntawm tes.
4. Txhim kho cytotoxicity los ntawm DNA ua rau cov neeg ua haujlwm puas tsuaj: Veliparib feem ntau siv nrog kev kho mob lossis kev kho hluav taws xob, uas ua rau muaj kev puas tsuaj DNA. Los ntawm inhibiting PARP, Veliparib tiv thaiv kev kho ntawm qhov kev puas tsuaj, yog li txhim kho cov teebmeem cytotoxic ntawm cov kev kho mob ntawm cov kab mob.
Hauv kev xaus, veliparib ua haujlwm los ntawm inhibiting PARP enzyme, uas ua rau muaj kev txhim kho DNA puas tsuaj thiab, thaum kawg, txhawb kev mob cell tuag, tshwj xeeb hauv cov hlwb uas twb muaj qhov tsis zoo hauv lawv cov DNA kho.
Dab tsi yog PARP Inhibitors siv rau
PARP inhibitors feem ntau kho cov kab mob ntawm tes, tshwj xeeb tshaj yog cov uas muaj cov txheej txheem kho DNA tsis zoo. Nov yog qee qhov kev siv tseem ceeb rau PARP inhibitors:
1. Cov kab mob ntawm zes qe menyuam: PARP inhibitors feem ntau siv los kho cov kab mob ntawm zes qe menyuam, tshwj xeeb tshaj yog cov uas muaj BRCA1 lossis BRCA2 hloov pauv. Lawv tau pom tias muaj txiaj ntsig zoo hauv kev kho mob thiab kho cov kab mob ntawm zes qe menyuam.
2. Cov kab mob hauv lub mis: Cov tshuaj tiv thaiv no kuj siv los kho cov kab mob ntawm lub mis, tshwj xeeb tshaj yog cov uas muaj BRCA hloov pauv. Lawv tuaj yeem siv los ua monotherapy lossis ua ke nrog lwm cov kev kho mob.
3. Prostate-mob hlwb: PARP inhibitors tau pom cov lus cog tseg hauv kev kho mob metastatic castration-resistant prostate-diseased cells (mCRPC) hauv cov neeg mob uas muaj kev hloov pauv hauv DNA kho cov noob, suav nrog BRCA1, BRCA2, thiab lwm yam homologous recombination kho (HRR) noob.
4. Cov kab mob pancreatic: Qee cov PARP inhibitors kho cov kab mob pancreatic hauv cov neeg mob uas muaj cov kab mob BRCA hloov pauv.
5. Lwm pawg kab mob ntawm tes: Cov kev tshawb fawb tab tom soj ntsuam kev ua tau zoo ntawm PARP inhibitors ntawm lwm hom kab mob, nrog rau cov kab mob uas tsis yog me me hauv lub ntsws (NSCLC), kab mob plab, thiab lwm yam.
Nws kuj tseem siv tau ua ke nrog lwm cov kev kho mob
1. Tshuaj Kho Mob: PARP inhibitors feem ntau siv nrog DNA ua rau cov tshuaj tua kab mob los txhim kho lawv cov txiaj ntsig.
2. Kev kho hluav taws xob: Lawv kuj tuaj yeem siv nrog kev kho hluav taws xob los tiv thaiv kev kho hluav taws xob vim DNA puas.
PARP inhibitors sawv cev rau kev nce qib tseem ceeb hauv kev kho mob rau qee cov kab mob, tshwj xeeb tshaj yog cov uas muaj cov kab mob tshwj xeeb hauv DNA kho txoj hauv kev.
Veliparib vS olaparib
Ob leeg veliparib thiab olaparib yog PARP inhibitors siv los kho cov kab mob, tab sis lawv txawv ntawm kev siv tshuaj kho mob, txheej txheem, thiab kev loj hlob. Ntawm no yog qhov sib piv ntawm ob:
Veliparib (ABT-888)
1. Mechanism of action: Inhibits PARP-1 thiab PARP-2, tiv thaiv kev kho ntawm ib leeg-strand DNA so. Tiv thaiv kev kho-induced DNA puas los ntawm kev kho, ua kom cov kev ua tau zoo ntawm hluav taws xob thiab tshuaj tua kab mob.
2. Daim ntawv thov kev kho mob: Ib qho tshuaj ntsuam xyuas hauv ntau qhov kev sim tshuaj. Nws tau kawm nyob rau hauv zes qe menyuam, mis, ntsws, thiab lwm yam kab mob ntawm tes, tshwj xeeb tshaj yog ua ke nrog lwm yam kev kho mob. Tej zaum nws yuav pab tau rau cov kab mob ntawm tes nrog BRCA kev hloov pauv thiab lwm yam kev kho DNA.
3. Kev pom zoo raws li txoj cai: Raws li cov ntaub ntawv tam sim no, veliparib tseem raug tshawb xyuas hauv kev tshawb fawb soj ntsuam thiab tsis tau txais kev pom zoo los ntawm lub koom haum tswj hwm (xws li FDA).
4. Kev sib xyaw ua ke: Nws feem ntau siv nrog lwm cov tshuaj khomob thiab kev siv hluav taws xob los txhim kho kev ua tau zoo.
Olaparib (Lynparza)
1. Mechanism of action: Inhibits PARP-1, PARP-2, thiab PARP-3, ua rau DNA puas thiab cell tuag. Tshwj xeeb zoo tiv thaiv BRCA1 lossis BRCA2 mutant hlwb vim yog hluavtaws lethality.
2. Kev siv tshuaj kho mob: Pom zoo siv rau hauv ntau cov kab mob ntawm tes, suav nrog zes qe menyuam, mis, pancreatic, thiab cov kab mob prostate. Nws yog tshwj xeeb tshaj yog haum rau tej yam kev mob nrog BRCA1/2 kev hloov pauv los yog lwm yam homologous recombination kho (HRR) deficiencies. Lawv tau siv los ua kev kho mob kom ncua sij hawm tshem tawm thiab kho cov kab mob siab heev.
3. Kev pom zoo raws li txoj cai: Nws tau pom zoo los ntawm cov koom haum tswj hwm xws li FDA rau ntau yam kev qhia. Muaj dav thiab siv hauv kev kho mob.
4. Kev sib xyaw ua ke: Nws tuaj yeem siv los ua monotherapy lossis ua ke nrog lwm yam tshuaj. Pom zoo rau kev siv nrog cov tshuaj khomob tshwj xeeb thiab cov kev kho mob tshwj xeeb.
Hauv cov ntsiab lus, thaum ob qho tshuaj yog PARP inhibitors nrog cov txheej txheem ntawm kev ua haujlwm zoo sib xws, olaparib yog qib siab dua txog kev pom zoo thiab tsim siv. Nyob rau tib lub sijhawm, veliparib tseem tab tom tshawb nrhiav hauv kev sim tshuaj ntsuam xyuas los txiav txim siab nws lub peev xwm thiab daim ntawv thov hauv kev kho tus mob.
Yog tias koj xav paub ntau ntxiv txog cov chaw tsim khoom Veliparib hydrochloride, koj tuaj yeem tiv tauj Xi'an Sonwu. Nyem rau email kom tau txais ABT888 hmoov zoo.
Email:sales@sonwu.com